Geode Capital Management’s Finch Therapeutics Group, Inc. Common Stock FNCH Stock Holding History

Geode Capital Management’s Portfolio FNCH Stock Details FNCH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q2	–	Sell	-6,944	Closed	-$81.9K	–	4821
2023 Q1	$81.9K	Sell	6,944 -46	-0.7%	-$610	﹤0.01%	4403
2022 Q4	$100K	Sell	6,990 -16	-0.2%	-$535	﹤0.01%	4404
2022 Q3	$351K	Buy	7,006 +3,558	+103%	+$247K	﹤0.01%	3915
2022 Q2	$293K	Sell	3,448 -1,900	-36%	-$162K	﹤0.01%	4045
2022 Q1	$806K	Buy	5,348 +309	+6%	+$71.3K	﹤0.01%	3713
2021 Q4	$1.51M	Sell	5,039 -79	-2%	-$30.3K	﹤0.01%	3514
2021 Q3	$2M	Buy	5,118 +434	+9%	+$185K	﹤0.01%	3352
2021 Q2	$1.98M	Buy	+4,684	New	+$2.03M	﹤0.01%	3270

Other funds holding FNCH

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

AMC

Avenir Management Company New York $43.8M AUM 101.91% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

LSAG

Lake Street Advisors Group Portsmouth, New Hampshire $2.17B AUM 16.99% 1-Year Est. Return

Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return

Bleichroeder LP New York $579M AUM 94.36% 1-Year Est. Return

TRCT

Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return

UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return

Ancora Advisors Cleveland, Ohio $4.7B AUM 19.05% 1-Year Est. Return

Geode Capital Management's FNCH Position: Q2 2023 in Review

Geode Capital Management sold out of Finch Therapeutics Group, Inc. Common Stock (FNCH) in Q2 2023, closing a stake of 6,944 shares — an estimated $81.9K sold.

Geode Capital Management first reported a position in FNCH in Q2 2021 and held it in 8 quarters. The position peaked at $2M in Q3 2021. 17 funds tracked by Wall St. Rank hold FNCH as of Q2 2023.

Geode Capital Management reported no remaining Finch Therapeutics Group, Inc. Common Stock position as of Q2 2023 after selling out during the quarter.
Geode Capital Management sold 6,944 Finch Therapeutics Group, Inc. Common Stock shares in Q2 2023, an estimated $81.9K.
Geode Capital Management first reported a position in Finch Therapeutics Group, Inc. Common Stock in Q2 2021 and held it in 8 quarters.
Geode Capital Management's Finch Therapeutics Group, Inc. Common Stock position peaked at $2M in Q3 2021.
17 funds tracked by Wall St. Rank held Finch Therapeutics Group, Inc. Common Stock as of Q2 2023.

Based on Geode Capital Management's 13F filing for Q2 2023, filed 11 Aug 2023.